1030832-46-2 Usage
Uses
Used in Pharmaceutical Industry:
2-BromoMethyl-4-trifluoroMethylbenzene boronic ester is used as a building block for the synthesis of various pharmaceuticals. Its unique reactivity and the presence of a trifluoromethyl group make it a valuable component in the development of new drugs with improved stability and lipophilicity.
Used in Organic Synthesis:
2-BromoMethyl-4-trifluoroMethylbenzene boronic ester is used as a reagent in cross-coupling reactions to form carbon-carbon bonds. Its versatility in organic synthesis allows for the preparation of a wide range of fine chemicals and complex organic molecules.
Used in Medicinal Chemistry:
2-BromoMethyl-4-trifluoroMethylbenzene boronic ester is used as a valuable tool in medicinal chemistry for the development of new drugs. Its enhanced stability and lipophilicity contribute to the design and synthesis of more effective and bioavailable pharmaceutical compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 1030832-46-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,0,8,3 and 2 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1030832-46:
(9*1)+(8*0)+(7*3)+(6*0)+(5*8)+(4*3)+(3*2)+(2*4)+(1*6)=102
102 % 10 = 2
So 1030832-46-2 is a valid CAS Registry Number.
1030832-46-2Relevant academic research and scientific papers
Novel compound and glucose detection method using same
-
, (2021/09/07)
The present invention relates to a novel compound having excellent glucose detection effect and a method for detecting glucose using the same. The novel compound of the present invention advantageously enhances the fluorescence characteristics of the improved Red shift and Stokes shift spectral properties, as well as providing excellent glucose sensitivity, and has an obvious commercial advantage of a simpler and less expensive optical sensing system upon insertion or proximity use in the human body.
2-METHYL-QUINAZOLINES
-
, (2018/10/19)
The present invention describes 2-methyl-quinazoline compounds of general formula (I), methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions. The 2-methyl substituted quinazoline compounds of general formula(I) effectively and selectively inhibit the Ras-Sos interaction without significantly targeting the EGFR receptor. They are therefore useful for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, such as cancer as a sole agent or in combination with other active ingredients.
